Therefore, [18F]75 isa promising candidate for translation to human brain PET imaging studieswith the potential to image tau aggregates not only in 4R-tauopathies,but also in 3R-tauopathies and mixed 3R/4R-tauopathies without theconfound of differential sources of off-target binding that are observedwith some of the current AD-tau PET radiopharmaceuticals. The gene discussed is MAPT; the disease is Alzheimer disease.